Fig. 4: CoVac501 induced protective humoral immune responses in cynomolgus macaques. | Cell Discovery

Fig. 4: CoVac501 induced protective humoral immune responses in cynomolgus macaques.

From: CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity

Fig. 4

a Schematic diagram of immunization, sample collection, and detection in cynomolgus monkeys. Cynomolgus monkeys (n = 2) were immunized with peptide vaccines in the following groups: saline, LY54–101 (F2), LY54–101 (AS03), LY54–101 + P67–101 (1:1, F2), LY54–101 + P67–101 (2:1, F2), and LY54 + P67 (1:1, F2) for three doses at days 0, 14, and 28. b–d Sera were collected from the monkeys and the levels of RBD-specific antibody were tested for different serum dilutions using ELISA. e–g Sera were collected from monkeys 28 (e) and 70 (f, g) days after the first dose of vaccine and ACE2-RBD blocking antibodies were tested for different serum dilutions using ELISA. h The neutralization of sera from cynomolgus monkeys 63 days after the first dose of vaccine for SARS-CoV-2 pseudovirus (Wuhan-1). i The neutralization of sera from cynomolgus monkeys 56 days after the first dose of vaccine for live SARS-CoV-2 in vitro was tested by microdose CPE assay. j RNA sequencing results were analyzed for memory B cells in CoVac501-vaccinated monkeys. All data are presented as the means ± SEM.

Back to article page